For research use only. Not for therapeutic Use.
JNJ-303 is a specific delayed rectifier Kv blocker. JNJ 303 can potent block IKs with an IC50 value of 64 nM. JNJ-303 can be used for the research of diabetes, obesity and central nervous system[1][2].
JNJ 303 can block IKs with an IC50 value of 64 nM[1].
JNJ 303 (3.3 μM) does not have any effects on other cardiac channels[1].
JNJ 303 induces QT-prolongations and causes unprovoked torsades de pointes (TdP)[1].
JNJ 303 recapitulates the Exn4-induced decrease in fasting blood glucose level in mice[2].
| Catalog Number | I010848 |
| CAS Number | 878489-28-2 |
| Synonyms | 2-(4-chlorophenoxy)-N-[5-(methanesulfonamido)-2-adamantyl]-2-methylpropanamide |
| Molecular Formula | C21H29ClN2O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C21H29ClN2O4S/c1-20(2,28-17-6-4-16(22)5-7-17)19(25)23-18-14-8-13-9-15(18)12-21(10-13,11-14)24-29(3,26)27/h4-7,13-15,18,24H,8-12H2,1-3H3,(H,23,25) |
| InChIKey | OSGIRCJRKSAODN-UHFFFAOYSA-N |
| SMILES | CC(C)(C(=O)NC1C2CC3CC1CC(C3)(C2)NS(=O)(=O)C)OC4=CC=C(C=C4)Cl |
| Reference | [1]. Julie Albrecht, et al. The effect of the KV7/KCNE 1 inhibitor JNJ 303 on heart slices and the L-type calcium channel of cardiac cells. [2]. Zhaohuan Huang, et al. Glucose-sensing glucagon-like peptide-1 receptor neurons in the dorsomedial hypothalamus regulate glucose metabolism. Sci Adv. 2022 Jun 10;8(23):eabn5345. |
